As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen Inc. (NASDAQ:AMGN) is a biotechnology powerhouse with an excellent track-record on developing and commercialising products targeting four main therapeutic areas: general medicine ...

Amgen stock slouched Wednesday after an Eli ... But excluding the benefit of Horizon's products, sales climbed a more modest 5%, said Phipps, the William Blair analyst. He noted the fourth-quarter ...

When talking about growth in the years to come, Amgen has several levers it can pull. For starters, we can look at already approved products with growth potential. Tepezza, which became part of ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, stocks that pay dividends regularly can be great addition ...

The main condition set by the FTC is that Amgen is prohibited from bundling any of its medicines with two of Horizon’s marketed products – Tepezza (teprotumumab) for thyroid eye disease (TED ...

CfOR strives to design, conduct, analyze, interpret and publish observational research that ultimately informs the safety, efficacy, effectiveness and economic value of Amgen products. Under ...

Equities research analysts at William Blair reduced their FY2024 earnings per share estimates for shares of Amgen in a ...

Amgen will present the full dataset at a future medical meeting. The drug was acquired by Horizon from its earlier developer Viela Bio in 2021 and was one of three products the company had on the ...